Home Online Features Boehringer's new zongertinib data demonstrates durable and clinically meaningful results in patients with HER2 (ERBB2)-mutant advanced NSCLC
Boehringer’s new zongertinib data demonstrates durable and clinically meaningful results in patients with HER2 (ERBB2)-mutant advanced NSCLC
Hand-out
Press Releases
Boehringer Ingelheim  
April 28, 2025

Boehringer’s new zongertinib data demonstrates durable and clinically meaningful results in patients with HER2 (ERBB2)-mutant advanced NSCLC

New data from the Phase Ib Beamion LUNG-1 trial were presented at AACR and simultaneously published in The New England Journal of MedicineData presented included an objective response rate (ORR)

avatar profile Olean Times Herald

Olean Times Herald

email Olean Times Herald

Local & Social